# Research Training in Academic Medical Oncology

> **NIH NIH T32** · UNIVERSITY OF TX MD ANDERSON CAN CTR · 2020 · $362,121

## Abstract

Project Abstract
The MD Anderson Cancer Center (MDACC) T32 Research Training in Academic Medical Oncology Program
capitalizes on the availability of highly qualified fellows from within the MDACC Hematology/Medical Oncology
fellowship program to provide two years of academic research training to selected first-year fellows who have
demonstrated strong commitment to a career as a physician scientist or translational clinical investigator in
Medical Oncology. The T32 training program is thus a “program within a program,” but has a separate and
distinct organizational and administrative structure with the following specific objectives: 1) To provide and
integrate robust didactic, clinical, and lab-based research components within a structured training program
focused on the conduct of innovative medical oncology-based research; 2) To prepare trainees for successful
careers in academic medicine as physician scientists and clinician investigators focused on novel discoveries
and their clinical translation to improve the outcomes of patients with cancer; and 3) To provide a broad range
of structured career development opportunities, including the development of skills necessary to obtain peer-
reviewed funding to support each trainees’ transition to a faculty position in academic medical oncology. Our
T32 program involves new leadership with Dr. Michael Davies and Dr. Katy Rezvani as Co-PIs, both
accomplished investigators with long-term commitments to education and established track records in
successfully mentoring trainees. The program involves an expanded panel of highly accomplished and
nationally/internationally recognized program faculty (including Drs. James Allison, Ron DePinho, Helen
Piwnica-Worms, Patrick Hwu, John Heymach and others), and provides a broad range of training opportunities
that fully exploits the unique research environment at MDACC. These opportunities include participation in new
and rapidly developing multidisciplinary research programs in genomic medicine, systems biology, targeted drug
development for personalized cancer therapy, and cancer immunotherapy, including cellular immune therapies
and hematopoietic transplantation. The program is also enhanced by the extensive programmatic and shared
resources of MD Anderson as an NCI-designated Comprehensive Cancer Center. The T32 program has been
highly successful in producing academic medical oncologists who have made a major impact on the field, with
88% of the T32 graduates in the past ten years successfully obtaining academic faculty appointments. This
renewal application includes additional plans for career development and mentorship to meet the challenges of
an increasingly competitive landscape for young investigators. Finally, our application includes an invigorated
program governance structure to further our development of the next generation of leaders in clinical,
translational, and laboratory-based oncology research.

## Key facts

- **NIH application ID:** 9935898
- **Project number:** 2T32CA009666-26
- **Recipient organization:** UNIVERSITY OF TX MD ANDERSON CAN CTR
- **Principal Investigator:** Michael Davies
- **Activity code:** T32 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $362,121
- **Award type:** 2
- **Project period:** 1994-09-30 → 2025-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9935898

## Citation

> US National Institutes of Health, RePORTER application 9935898, Research Training in Academic Medical Oncology (2T32CA009666-26). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9935898. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*